ZURICH, Switzerland, March 15 /PRNewswire/ -- Prionics AG, the world
leader in testing procedures for bovine spongiform encephalopathy (BSE), today
issued the following statement in response to the announcement by the U.S.
Department of Agriculture (USDA) regarding additional BSE surveillance
"Prionics praises the approach taken by the USDA and its decision to
bolster the surveillance, detection and response program," said Dr. Markus
Moser, CEO of Prionics. "The USDA's additional actions will further
strengthen U.S. prevention systems and the confidence of both consumers and
customers around the world."
"Prionics offers both rapid test technologies, the ELISA and the Western
Blot, but recommends the Western Blot for the current surveillance system in
the U.S. because of its flawless record of returning no false positive
results," added Moser. "False positives cause a loss in consumer confidence
and can have a detrimental economic impact, particularly in BSE free countries
like the United States."
Prionics(R)-Check WESTERN is considered by many animal health authorities
internationally to be the most accurate rapid-test procedure for BSE in the
world. In fact, in 2003, the USDA stated a preference for Western Blot
technology particularly in BSE free countries. Prionics(R)-Check WESTERN
rapid BSE test has been used in more than 18 million of the 30 million BSE
tests conducted worldwide between 2001 and 2003 -- without returning a false
About Prionics AG
Prionics AG has the largest number of scientists in the industry focused
on BSE and works closely with a network of prion and neurological experts
around the world. Prionics' surveillance concept has led to the establishment
of official EU-wide BSE screening programs in 2001, and Prionics(R)-Check
WESTERN is the preferred test in these programs. Prionics AG, based in
Zurich, Switzerland, is an ISO 9001 certified company with production
facilities in Switzerland and the U.S. and currently employs 100 people. For
more information about Prionics, please visit www.prionics.ch.
SOURCE Prionics AG